Author: OurCrowd

[Innoviz in PR Newswire] Innoviz expands collaboration with a major customer, adding InnovizTwo for new light commercial vehicle

May 17, 2023 |

TEL AVIV, Israel, May 17, 2023 /PRNewswire/ — Innoviz Technologies Ltd. (NASDAQ: INVZ) (the “Company” or “Innoviz”), a leading Tier-1 supplier of high-performance automotive grade LiDAR sensors and perception software, today announced that a major existing leading global automotive customer aims to expand its use of the InnovizTwo LiDAR to an existing light commercial vehicle program. With a mid-decade SOP target, the program is on an accelerated track, with an agreed framework, pending finalizing technical requirements and commercial terms. Potential financial contributions from this program are anticipated to begin this year and played an important role in the decision to update previously communicated 2023 commercial and financial targets. Read more...

Read More

[data.world in GlobeNewswire] data.world launches the data catalog platform with generative AI Bots

May 17, 2023 |

AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) — data.world today announced the introduction of the data.world Data Catalog Platform with new Generative AI-powered capabilities for improving data discovery. data.world is the industry’s most-used data catalog with more than 2 million users, including enterprise customers with tens of thousands of active users. Now with native Generative AI integrations, even more people can use data.world to discover data and unlock organizational knowledge – regardless of expertise level. Read more...

Read More

[Alpha Tau in GlobeNewswire] Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

May 17, 2023 |

JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with squamous cell carcinoma of the vulva has been treated in a feasibility and safety study of Alpha DaRT at Addenbrookes Hospital of the Cambridge University Hospitals NHS Foundation Trust in Cambridge, England. Read...

Read More